gwpharma

GW Pharma takes back control of UK Sativex sales from Bayer

pharmafile | March 2, 2020 | News story | Sales and Marketing Bayer, GW Pharma, Sativex, UK 

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis drug Sativex (delta-9-tetrahydrocannabinol and cannabidiol), known by the generic name nabiximols, in the UK.

Previously, all sales in the UK of Sativex were exclusively managed by GW Pharma’s partner Bayer; this has been the case since the drug’s approval in 2010 by the

 Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of spasticity originating from multiple sclerosis.

However, this model will change going forward. As of the new arrangement agreed between GW and Bayer, there will be a “transitional period” until the end of this year, with GW assuming all commercialisation responsibilities relating to the sale of Sativex beyond 31 December 2020.

Advertisement

The pair committed to maintain “a seamless transition for health care professionals and patients” during this interim period, with no planned changes to day-to-day business practice.

Matt Fellows

Related Content

Evotec and Bayer announce new kidney disease study

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Addenbrooke’s hospital offers first self-service digital eye test

Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …

Digital Control Room, a major pharma provider, wins King’s Award for Enterprise

Buckingham Palace has announced that Digital Control Room, a software platform that monitors companies’ online …

The Gateway to Local Adoption Series

Latest content